Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.143196 http://scihub22266oqcxt.onion/10.1172/jci.insight.143196 33571168!8026191!33571168     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2021 ; 6 (6): ä Nephropedia Template TP {{tp|p=33571168|t=2021. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |pdf=|usr=}}{{33571168}} gab.com Text Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33571168 #FOAvip Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti-SARS-CoV-2 Abs. Radiographic and laboratory evaluation confirmed all 51 treated patients had COVID-19 pneumonia. Fresh or frozen CCP from donors with high titers of neutralizing Abs was administered. The nonmechanically ventilated patients (n = 36) had an intubation rate of 13.9% and a 30-day survival rate of 88.9%, and the overall survival rate for a comparative group based on network data was 72.5% (1625/2241). Patients had negative nasopharyngeal swab rates of 43.8% and 73.0% on days 10 and 30, respectively. Patients mechanically ventilated had a day-30 mortality rate of 46.7%; the mortality rate for a comparative group based on network data was 71.0% (369/520). All evaluable patients were found to have neutralizing Abs on day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60. The only adverse event was a mild rash. In this study on patients with COVID-19 disease, we show therapeutic use of CCP was safe and conferred transfer of Abs, while preserving endogenous immune response. Twit Text FOAVip Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33571168 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33571168 #FOAvip English Wikipedia <ref>{{Cite pmid|33571168}}</ref> Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma #MMPMID33571168 Donato ML; Park S; Baker M; Korngold R; Morawski A; Geng X; Tan M; Ip A; Goldberg S; Rowley S; Chow K; Brown E; Zenreich J; McKiernan P; Buttner K; Ullrich A; Long L; Feinman R; Ricourt A; Kemp M; Vendivil M; Suh H; Balani B; Cicogna C; Sebti R; Al-Khan A; Sperber S; Desai S; Fanning S; Arad D; Go R; Tam E; Rose K; Sadikot S; Siegel D; Gutierrez M; Feldman T; Goy A; Pecora A; Biran N; Leslie L; Gillio A; Timmapuri S; Boonstra M; Singer S; Kaur S; Richards E; Perlin DS JCI Insight 2021[Mar]; 6 (6): ä PMID33571168show ga Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti-SARS-CoV-2 Abs. Radiographic and laboratory evaluation confirmed all 51 treated patients had COVID-19 pneumonia. Fresh or frozen CCP from donors with high titers of neutralizing Abs was administered. The nonmechanically ventilated patients (n = 36) had an intubation rate of 13.9% and a 30-day survival rate of 88.9%, and the overall survival rate for a comparative group based on network data was 72.5% (1625/2241). Patients had negative nasopharyngeal swab rates of 43.8% and 73.0% on days 10 and 30, respectively. Patients mechanically ventilated had a day-30 mortality rate of 46.7%; the mortality rate for a comparative group based on network data was 71.0% (369/520). All evaluable patients were found to have neutralizing Abs on day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60. The only adverse event was a mild rash. In this study on patients with COVID-19 disease, we show therapeutic use of CCP was safe and conferred transfer of Abs, while preserving endogenous immune response. |*Plasma[MESH] |*Severity of Illness Index[MESH] |Aged[MESH] |Antibodies, Neutralizing/blood/*therapeutic use[MESH] |Antibodies, Viral/blood/*therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/mortality/*therapy/virology[MESH] |Convalescence[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Immunocompromised Host[MESH] |Immunoglobulin G/blood/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Pneumonia[MESH] |Respiration, Artificial[MESH]Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumon(epmc).pdf DeepDyve Pubget Overpricing